摘要
背景:L-四氢巴马汀(L-THP)是一种四氢原贝贝丁异喹啉生物碱。据报道含有异喹啉生物碱的植物化合物显示出对包括白血病的许多人类癌细胞系的潜在作用。我们假设L-THP是一种异喹啉生物碱,可能是一种抗急性淋巴细胞白血病(ALL)的潜在分子,在本研究中,我们评估L-THP对p53缺陷型白血病EU-4细胞系的体外作用。 方法:用于研究,使用p53无效白血病EU-4细胞并用LTHP处理。测定细胞的凋亡程度和存活力。通过western印迹和PCR研究完成凋亡相关蛋白如XIAP和MDM2的表达。 MDM2和XIAP的表达被小干扰RNA(siRNA)击倒。 结果:研究结果提示,L-THP引起EU-4细胞中XIAP介导的p53依赖性凋亡。随着剂量和时间的增加,L-THP的处理导致XIAP蛋白水平的降低。 L-THP通过抑制MDM2的表达,参与蛋白酶体依赖途径,导致XIAP蛋白表达下调。此外,实验的结果表明由于L-THP抑制XIAP或通过siRNA抑制白血病细胞对阿霉素的敏感性增加。 结论:研究结果证实L-THP通过抑制与蛋白酶体依赖性途径相关的MDM2和提高EU-4细胞对多柔比星的敏感性而下调XIAP蛋白而导致p53非依赖性细胞凋亡。 L-THP引起caspase活化并导致细胞凋亡,L-THP可能是一种新的特异性诱导p53无效白血病EU-4细胞凋亡的分子。
关键词: L-四氢巴马汀,异喹啉生物碱,白血病,EU-4细胞,XIAP,MDM2。
Current Molecular Medicine
Title:L-Tetrahydropalmatine Induces Apoptosis in EU-4 Leukemia Cells by Down-Regulating X-Linked Inhibitor of Apoptosis Protein and Increases the Sensitivity Towards Doxorubicin
Volume: 17 Issue: 3
关键词: L-四氢巴马汀,异喹啉生物碱,白血病,EU-4细胞,XIAP,MDM2。
摘要: Background: L-Tetrahydropalmatine (L-THP) is a tetra-hydro protoberberine isoquinoline alkaloid. The phyto-compounds bearing isoquinoline alkaloids have been reported to show a potential effect against a number of human cancers cell lines including leukemia. We hypothesized that L-THP, being an isoquinoline alkaloid, could be a potential molecule against acute lymphoblastic leukemia (ALL), in this study, we evaluate L-THP against p53 deficient leukemia EU-4 cell lines in vitro.
Methods: For the study, p53 null leukemia EU-4 cells were used and treated with LTHP. The extent of apoptosis and viability of cells were determined. Expression of apoptosis related proteins such as XIAP and MDM2 was done by western blot and PCR studies. The expression of MDM2 and XIAP was knocked down by small interfering RNA (siRNA).
Results: Outcomes of the study suggested that L-THP caused p53-indipendent apoptosis mediated by XIAP in EU-4 cells. The treatment of L-THP caused a decrease in the levels of XIAP protein with increasing dose and time. L-THP caused down-regulation of XIAP protein via inhibiting the expression of MDM2 and involving proteasomedependent pathway. Also, the outcomes of experiments suggested increased sensitivity of leukemia cells towards doxorubicin due to the inhibition of XIAP by L-THP or by siRNA.
Conclusion: Findings of the study confirm that L-THP resulted in p53 independent apoptosis via down-regulating XIAP protein by inhibiting MDM2 associated with proteasome-dependent pathway and increased sensitivity of EU-4 cells against doxorubicin. L-THP caused activation of caspase and resulted in apoptosis, L-THP may be a novel molecule for inducing apoptosis specifically in p53 null leukemia EU-4 cells.
Export Options
About this article
Cite this article as:
L-Tetrahydropalmatine Induces Apoptosis in EU-4 Leukemia Cells by Down-Regulating X-Linked Inhibitor of Apoptosis Protein and Increases the Sensitivity Towards Doxorubicin, Current Molecular Medicine 2017; 17 (3) . https://dx.doi.org/10.2174/1566524017666170718170000
DOI https://dx.doi.org/10.2174/1566524017666170718170000 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nilotinib Therapy in Chronic Myelogenous Leukemia: The Strength of High Selectivity on BCR/ABL
Current Drug Targets Pleiotropic Effect of Mahanine and Girinimbine Analogs: Anticancer Mechanism and its Therapeutic Versatility
Anti-Cancer Agents in Medicinal Chemistry Potential Therapeutic Approaches for the Treatment of Acute Myeloid Leukemia with AML1-ETO Translocation
Current Cancer Drug Targets Cancer Immunotherapy Using Gene-Modified Dendritic Cells
Current Gene Therapy Cancer and Stem Cells
Current Cancer Therapy Reviews The Metaboloepigenetic Dimension of Cancer Stem Cells: Evaluating the Market Potential for New Metabostemness-Targeting Oncology Drugs
Current Pharmaceutical Design Management of Inflammatory Bowel Disease Patients with a Cancer History
Current Drug Targets Role of Platelets in Angiogenesis in Health and Disease
Current Angiogenesis (Discontinued) GEMSP: A New Therapeutic Approach to Multiple Sclerosis
Central Nervous System Agents in Medicinal Chemistry The Use of Infliximab in Dermatology
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Emerging Strategies and Challenges for Controlled Delivery of Taxanes: A Comprehensive Review
Current Drug Metabolism Transfusion-related Acute Lung Injury: An Overview
Current Pharmaceutical Design Targeting MDM2 and MDMX in Retinoblastoma
Current Cancer Drug Targets New Strategies in the Management of Children and Adolescents with Proliferative Lupus Nephritis
Current Rheumatology Reviews Targeting Transcription Factors for Cancer Therapy
Current Pharmaceutical Design Growth Inhibition of Various Human Cancer Cell Lines by Imperatorin and Limonin from Poncirus Trifoliata Rafin. Seeds
Anti-Cancer Agents in Medicinal Chemistry Progestins for Symptomatic Endometriosis: Results of Clinical Studies
Current Drug Therapy Novel Agents in CNS Myeloma Treatment
Central Nervous System Agents in Medicinal Chemistry Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
Current Medicinal Chemistry Inhibitors of the Ubiquitin-Proteasome System and the Cell Death Machinery: How Many Pathways are Activated?
Current Molecular Pharmacology